International Myotonic Dystrophy Awareness Day to be Observed September 15th
The Neuromuscular Disease Network for Canada (NMD4C) and Muscular Dystrophy Canada (MDC) are proud to be members of a global alliance of myotonic dystrophy (DM) focused organizations who have united to declare an International Day of Awareness for DM, to be observed on the 15th of September each year. This September will mark the inaugural International Myotonic Dystrophy Awareness Day, and there are many exciting events and activities planned from organizations around the world to recognize this day and raise awareness for DM.
Announced on February 28th to honor International Rare Disease Day 2021, International DM Awareness Day aims to garner the attention of the wider general public, policy makers, regulators, biopharmaceutical representatives, researchers, health care professionals, and anyone with an interest in changing the future of myotonic dystrophy. Raising awareness of myotonic dystrophy will help improve service provision, basic research, drug development, and policymaking related to the disease.
One of the network’s ongoing activities around International DM Awareness Day has been to advocate for official recognition by governments at both the provincial and federal level. We are happy to share that through the combined efforts of MDC, the NMD4C, and Myotonic Dystrophy Foundation (MDF) Support Group Facilitator and NMD4C Investigator Teresa Buffone, the Province of Manitoba has officially proclaimed September 15th, 2021 to be International Myotonic Dystrophy Awareness Day! We hope to see further proclamations from the federal and provincial levels of government as we continue to advocate for recognition of this day.
MDC will also be hosting a webinar to recognize this year’s International DM Day. Myotonic 101 with Dr. Cynthia Gagnon will introduce the basic facts and latest research about Myotonic dystrophy. This webinar will answer questions such as:
- What is Myotonic muscular dystrophy?
- What are the symptoms/signs of Myotonic muscular dystrophy?
- How is Myotonic muscular dystrophy diagnosed? Prognosis?
- What are treatment options?
- What about supportive treatments for Myotonic muscular dystrophy?
- What research is being done on Myotonic muscular dystrophy in Canada?
Register here for the event!
Further information about International DM Awareness Day can be found on the MDF website here. Check out what other organizations have planned for September 15th, and find out how you can get involved!
Read next...
NMD4C to Develop a List of Canadian Neuromuscular Research Labs to Support Research Collaborations and Training
We are excited to launch an initiative from the NMD4C cell and animal-based NMD research tasks to develop a centralized list of Canadian neuromuscular research labs, and we need your help to collect this information!
MDC and NMD4C Hiring Full-Time Clinical Trials and Community Practice Manager
Join our team of dedicated colleagues and volunteers in breaking down barriers for the neuromuscular community and help bring clinical trials to Canada!
Annual NMD4C Early-Career Awards Program Accepting Applications
We are excited to launch the second year of the NMD4C Early-Career Awards for 2024!
NMD4C Pre-clinical Science Pillar Seeking Trainee Input
The NMD4C cell and animal-based research team is actively seeking the input of neuromuscular trainees to help inform our activities. If you are willing to participate in a committee that will meet periodically to share input on NMD4C cell and animal-based research activities, we want to hear from you!
NMD4C Investigators Dr Rashmi Kothary and Dr Natasha Chang Receive MDC Awards
We are excited to share that NMD4C investigators Dr Rashmi Kothary, and Dr Natasha Chang received the Dr George Karpati Award for Researcher of the Year and Rising Clinician/Researcher Award respectively from Muscular Dystrophy Canada
Vamorolone receives approval by the FDA in the US and positive opinion from CHMP in the EU for use in the treatment of Duchenne muscular dystrophy.
The FDA approved vamorolone on October 26, 2023 for the treatment of DMD in the US, while the CHMP has issued a positive opinion for vamorolone for the treatment of DMD in the EU.